Pseudovax hydrochloride for Pseudomyxoma peritonei

Inclusion criteria

• {"criterion_text":"- 1.\tThe subject is ≥ 18 years of age on the day of signing the informed consent form, able to provide written informed consent and can understand and agree to comply with the requirements of the study and the schedule of assessments.\n- 8b). b.\tMale subject: Sexually active males must be willing to use a condom during sex for the duration of the study and for ≥ 6 months after the last dose of IMP. Males must also be willing to abstain from donating sperm during the same period.\n- 2.\tConfirmed diagnosis of recurrent or non-resectable PMP with no other available treatment options that are expected to be efficacious.\n- 3.\tThe subject’s tumor must carry a mutation in the GNAS oncogene*\n- 4.\tSubjects must have peritoneal tumor distribution at screening that, in the opinion of the Investigator, is suitable for repeat biopsies: Up to 3 biopsies of target tissue are planned for subjects that complete the study.\n- 5.\tAdequate organ, bone marrow, liver, and renal function at screening, including: a). Absolute neutrophil count: ≥ 1,5 x10^9/L. b). Platelets: ≥ 100 x10^9/L. c). Hemoglobin: ≥ 9 x10^9/L. d). Creatinine ≤ 1,5 upper limit normal (ULN) OR measured/calculated GFR ≥60 mL/min. e). Albumin ≥ 30 g/L. f).\tTotal bilirubin ≤ 1,5 ULN. g). ASAT and ALAT ≤ 3 ULN. h). International Normalized Ratio (INR) ≤ 1,5 ULN and Activated Partial Thromboplastin Time (TT) ≤ 1,5 ULN unless subject is receiving anticoagulant therapy.\n- 6.\tECOG performance status of 0 or 1.\n- 7.\tLife expectancy of >6 months, at the time of signing the informed consent.\n- 8.\tWomen of childbearing potential must have a negative serum pregnancy test within 48 hours of the first study intervention, and must not be breast-feeding.\n- 8a). a.\tFemale participant: i.\tUnless documented not to have childbearing potential: Subject is willing to use contraceptive measures for the duration of the study, and ≥ 6 months after the last dose of IMP, as prescribed by the protocol (according to the applicable guidance: CTFG, 2020). The Investigator should counsel women of childbearing potential of the importance of pregnancy prevention. ii.\tWomen of childbearing potential must have a negative serum pregnancy test within 48 hours of the first study intervention."}

Exclusion criteria

• {"criterion_text":"- 1.\tPatient has Eastern Cooperative Oncology Group performance status 2 or worse.\n- 10.\tKnown active hepatitis B or C, or is known to be HIV-positive.\n- 11.\tAny condition that required systemic treatment with either corticosteroids (> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before the first dose of IMP. Note: Subjects who are currently or have previously been on any of the following steroid regimens are not excluded: Adrenal replacement steroid (dose ≤ 10 mg daily of prednisone or equivalent); Topical, ocular, intra-articular, intranasal, or inhaled corticosteroid with minimal systemic absorption; Short course (≤ 7 days) of corticosteroid prescribed prophylactically (eg, for contrast dye allergy) or for the treatment of a non-autoimmune condition (eg, delayed-type hypersensitivity reaction caused by contact allergen).\n- 12.\tActive autoimmune diseases or history of autoimmune diseases that may relapse. Note: Subjects with the following diseases are not excluded and may proceed to further screening, controlled Type I diabetes, hypothyroidism (provided it is managed with hormone replacement therapy only), controlled celiac disease skin diseases not requiring systemic treatment (eg, vitiligo, psoriasis, alopecia), any other disease that is not expected to recur in the absence of external triggering factors.\n- 13.\tSevere infections within 4 weeks before first dose of IMP, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.\n- 14.\tTherapeutic oral or intravenous antibiotics within 2 weeks before first dose of IMP\n- 15.\tAny major surgical procedure requiring general anesthesia ≤ 28 days before first dose of IMP.\n- 16.\tPrior allogeneic stem cell transplantation or organ transplantation\n- 17.\tCardiac chest pain, defined as moderate pain that limits instrumental activities of daily living, ≤ 28 days before first dose of IMP.\n- 18.\tPulmonary embolism ≤ 28 days before first dose of IMP.\n- 19.\tHistory of acute myocardial infarction ≤ 6 months before first dose of IMP.\n- 2.\tBlood transfusion or growth factor support ≤ 14 days before sample collection at screening.\n- 20.\tHistory of heart failure meeting New York Heart Association (NYHA) Classification III or IV (Appendix 6) ≤ 6 months before first dose of IMP.\n- 21.\tSubject has had any event of ventricular arrhythmia ≥ Grade 2 in severity ≤ 6 months before first dose of IMP.\n- 22.\tSevere hypersensitivity (≥grade 3) to chemotherapy, any other biologic drug or the contents or preservatives of any of the study drugs.\n- 23.\tHistory of cerebrovascular accident ≤ 6 months before first dose of IMP.\n- 24.\tSubject has underlying medical conditions (including laboratory abnormalities) or alcohol or drug abuse or dependence that, will be unfavorable for the administration of study drug or affect the explanation of drug toxicity or AEs or result in insufficient or might impair compliance with study conduct.\n- 25.\tAny reason why, in the opinion of the investigator, the patient should not participate.\n- 11.\tHistory of interstitial lung disease, non-infectious pneumonitis or uncontrolled diseases including pulmonary fibrosis, acute lung diseases, etc.\n- 12.\tSevere chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy, including tuberculosis infection, etc.\n- 2.\tBlood transfusion or growth factor support ≤ 14 days before sample collection at screening.\n- 3.\tActive malignancy the past 3 years except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast)\n- 4.\tEnrollment in another interventional trial that, in the opinion of the Investigator, could influence the outcome of this study.\n- 5.\tSubject has within the last 30 days received any other interventional therapy that, in the opinion of the Investigator, could influence the outcome of this study.\n- 6.\tPregnancy or lactating female."}

Primary endpoints

• {"endpoint_text":"- Incidence (rate) of IMP-related adverse events","definition_or_measurement_approach":""}
• {"endpoint_text":"- T cell responses against the vaccine peptide in blood samples and skin","definition_or_measurement_approach":"Measured as T cell responses assessed in blood samples and skin (as stated: 'in blood samples and skin')."}

Secondary endpoints

• {"endpoint_text":"- Progression-free survival, measured as the number of months from date of first treatment until disease progression or death from any cause","definition_or_measurement_approach":"Measured as the number of months from date of first treatment until disease progression or death from any cause."}

Norway

Earliest CTIS Part Ii Submission Date

15-07-2025

Latest Decision Or Authorization Date

19-03-2026

Processing Time Days

247

Number Of Sites

1

Number Of Participants

10

Primary sponsor

Full Name

Oslo University Hospital HF

Organisation Type

Hospital/Clinic/Other health care facility

Country Of Registered Address

Norway